title: The impact of proteomics in the understanding of the molecular basis of Paclitaxel-resistance in ovarian tumors.
abstract: The current therapy for ovarian cancer has advanced from alkylating agents, to a combination of carboplatinum and paclitaxel offering increased survival. Although most patients respond to this first-line therapy, initially, the majority of these patients relapse within 2 years. The mechanisms responsible for acquired drug resistance in ovarian cancer have been elucidated only in part. They include i) enhanced drug export, ii) activation/inhibition of intracellular signalling pathways, iii) molecular alterations in tubulin isotype composition. A better understanding of these mechanisms is needed, in order to develop new approaches, aimed at overcoming resistance to anticancer agents, and to reveal the complexity of causes, which contribute to drug resistance. In this review we offer an updated overview of proteomic studies on the molecular mechanisms of paclitaxel resistance. These proteomic studies also identify potential targets for modulating drug resistance, that could be predictive of response to chemotherapy in ovarian carcinomas.
authors.affiliation: Laboratory of General Physiology, Department of Biological and Environmental Sciences and Technologies, University of Salento, via Monteroni 73100, Lecce, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Vergara
authors.forename: A
authors.initials: A
authors.lastname: Tinelli
authors.forename: A
authors.initials: A
authors.lastname: Iannone
authors.forename: M
authors.initials: M
authors.lastname: Maffia
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D017239:Paclitaxel / Q000627:therapeutic use*; D040901:Proteomics / Q000379:methods*; D014404:Tubulin / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; C498585:TUBB3 protein, human; D014404:Tubulin; D017239:Paclitaxel